Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped. Yahoo Finance host Josh Lipton breaks down the day's top ...

At 23.8 times forward earnings, Vertex stock trades in line with the broader S&P 500 index, which is at 23.6 times earnings -- a surprising valuation for a company with a dominant market share and ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

This was the stock's second consecutive day of losses.

Vertex Pharmaceuticals (NASDAQ ... But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold ...

The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth Stock Is a No-Brainer Buy on ...

The stock's fall snapped a four-day winning streak.

Notably, Vertex Pharmaceuticals (NASDAQ ... Learn More » With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock ...